Trabectedin in the treatment of soft tissue sarcomas: up to date data-Reference-Cited by-同舟云学术

Trabectedin in the treatment of soft tissue sarcomas: up to date data

Published:2021-11-17 Issue:3 Volume:13 Page:16-26
ISSN:2782-3687
Container-title:Bone and soft tissue sarcomas, tumors of the skin
language:
Short-container-title:jour

Author:

Fedenko A. A.¹^ORCID,Tararykova A. A.²^ORCID

Affiliation:

1. National Medical Research Radiological Center, Ministry of Health of Russia

2. N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Abstract

Soft tissue sarcomas are a rare heterogeneous group of malignant tumors with mesenchymal nature. Soft tissue sarcomas accounts for less than 1 % of all cancers. Low efficiency of chemotherapy for soft tissue sarcomas, especially in advanced disease, is a burning issue. Trabectedin is one of the active agents approved for the treatment of advanced soft tissue sarcomas after the failure of standard chemotherapy. The article provides a literature review of the latest world-wide data of the effectiveness and role of trabectedin in the modern approach of soft tissue sarcomas treatment.

Publisher

Publishing House ABV Press

Reference41 articles.

1. Malignant neoplasms in Russia in 2019 (morbidity and mortality). Ed. by A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadov. Moscow: P.A. Herzen Moscow State Medical Research Institute – branch of the Federal State Budgetary Institution "NMIC of Radiology" of Ministry of Health of Russia, 2020. 252 p..

2. Amercan Cancer Society. Cancer Facts & Figures 2017. Atlanta Am Cancer Soc 2017. Avaliable at: https://www.cancer.org/research/cancer-facts-statistics/all-cancerfacts-figures/cancer-facts-figures-2017.html.

3. Le Cesne A., Blay J.-Y., Cupissol D. et al. A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial. Ann Oncol 2021;32(8):1034–44. DOI: 10.1016/j.annonc.2021.04.014.

4. Delaloge S., Yovine A., Taamma A. et al. Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients – preliminary evidence of activity. J Clin Oncol 2001;19(5):1248–55. DOI: 10.1200/JCO.2001.19.5.1248.

5. Yovine A., Riofrio M., Blay J.Y. et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004;22(5):890–9. DOI: 10.1200/JCO.2004.05.210.